Grape seed extract and diabetes drug tested for prostate cancer side effects

NCT ID NCT02946996

Terminated Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a grape seed extract called OPC or the diabetes drug metformin could lower levels of AGEs (advanced glycation endproducts) in men with prostate cancer who are on hormone therapy. The trial planned to enroll 41 participants but was terminated early. The main goal was to see if these agents could reduce AGE levels by at least 30% in half of the patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPC (grape seed extract derivative) and metformin
What this could lead to: If successful, this could point toward a way to reduce AGE levels, which might help manage side effects of hormone therapy in prostate cancer patients.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. It is unclear if reducing AGE levels will have any meaningful benefit for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.